Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Lisa Bero to Drug Industry

This is a "connection" page, showing publications Lisa Bero has written about Drug Industry.

 
Connection Strength
  
 
 
16.835
  
  1. Grundy Q, Rudner N, Klein T, Ladd E, Hart D, MacIsaac M, Bero L. "I never thought of it as payment": Qualitative evaluation of workshops with advanced practice registered nurses on pharmaceutical industry payment reporting. J Am Assoc Nurse Pract. 2025 Jan 01; 37(1):51-60.
    View in: PubMed
    Score: 0.854
  2. Grundy Q, Held F, MacIsaac M, Baugh CM, Campbell EG, Bero L. Quantifying Industry Spending on Promotional Events Using Open Payments Data. JAMA Health Forum. 2024 Jun 07; 5(6):e241581.
    View in: PubMed
    Score: 0.821
  3. Grundy Q, Held F, Hart D, Baugh CM, Ladd E, Campbell E, Bero L. Characteristics of Advanced Practice Nurses Receiving Top Industry Payments and Their Practice Settings: a Cross-sectional Study. J Gen Intern Med. 2024 May; 39(7):1142-1148.
    View in: PubMed
    Score: 0.790
  4. Grundy Q, Huyer LD, Parker L, Bero L. Branded Care: The Policy Implications of Pharmaceutical Industry-Funded Nursing Care Related to Specialty Medicines. Policy Polit Nurs Pract. 2023 Feb; 24(1):67-75.
    View in: PubMed
    Score: 0.727
  5. Karanges EA, Nangla C, Parker L, Fabbri A, Farquhar C, Bero L. Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study. BMJ Open. 2021 08 31; 11(9):e049710.
    View in: PubMed
    Score: 0.678
  6. Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. Aust J Gen Pract. 2020 03; 49(3):151-154.
    View in: PubMed
    Score: 0.611
  7. Parker L, Fabbri A, Grundy Q, Mintzes B, Bero L. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ. 2019 12 12; 367:l6694.
    View in: PubMed
    Score: 0.602
  8. Behdarvand B, Karanges EA, Bero L. Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study. BMJ Open. 2019 08 20; 9(8):e030253.
    View in: PubMed
    Score: 0.589
  9. Parker L, Karanges EA, Bero L. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study. BMJ Open. 2019 02 19; 9(2):e024928.
    View in: PubMed
    Score: 0.569
  10. Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, Bero L. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. BMJ Open. 2019 02 05; 9(2):e025864.
    View in: PubMed
    Score: 0.567
  11. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Med. 2018 10; 44(10):1603-1612.
    View in: PubMed
    Score: 0.549
  12. Parker L, Williams J, Bero L. Ethical drug marketing criteria for the 21st century. BMJ. 2018 Apr 30; 361:k1809.
    View in: PubMed
    Score: 0.538
  13. Mintzes B, Swandari S, Fabbri A, Grundy Q, Moynihan R, Bero L. Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study. BMJ Open. 2018 02 13; 8(2):e019027.
    View in: PubMed
    Score: 0.530
  14. Fabbri A, Grundy Q, Mintzes B, Swandari S, Moynihan R, Walkom E, Bero LA. A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. BMJ Open. 2017 06 30; 7(6):e016701.
    View in: PubMed
    Score: 0.508
  15. Moynihan R, Bero L. Toward a Healthier Patient Voice: More Independence, Less Industry Funding. JAMA Intern Med. 2017 03 01; 177(3):350-351.
    View in: PubMed
    Score: 0.496
  16. Lundh A, Bero L. The ties that bind. BMJ. 2017 Jan 17; 356:j176.
    View in: PubMed
    Score: 0.492
  17. Grundy Q, Fabbri A, Mintzes B, Swandari S, Bero L. The Inclusion of Nurses in Pharmaceutical Industry-Sponsored Events: Guess Who Is Also Coming to Dinner? JAMA Intern Med. 2016 11 01; 176(11):1718-1720.
    View in: PubMed
    Score: 0.485
  18. Anglemyer AT, Krauth D, Bero L. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis. BMC Med Res Methodol. 2015 Mar 06; 15:12.
    View in: PubMed
    Score: 0.432
  19. Bero L. Bias related to funding source in statin trials. BMJ. 2014 Oct 03; 349:g5949.
    View in: PubMed
    Score: 0.420
  20. Formoso G, Marata AM, Magrini N, Bero L. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014 Sep 15; (9):ED000090.
    View in: PubMed
    Score: 0.418
  21. Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770.
    View in: PubMed
    Score: 0.400
  22. Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013 Apr 08; 173(7):580-1.
    View in: PubMed
    Score: 0.379
  23. Nkansah N, Nguyen T, Iraninezhad H, Bero L. Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. Public Health Nutr. 2009 Oct; 12(10):1931-7.
    View in: PubMed
    Score: 0.285
  24. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ. 2007 Dec 08; 335(7631):1202-5.
    View in: PubMed
    Score: 0.261
  25. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007 Apr; 4(4):e134.
    View in: PubMed
    Score: 0.249
  26. Pokorny AMJ, Bero LA, Fox P, Karikios DJ, McEwin EJ, Moynihan R, Mintzes B. Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study. BMJ Open. 2023 05 26; 13(5):e065719.
    View in: PubMed
    Score: 0.191
  27. Shamasunder B, Bero L. Financial ties and conflicts of interest between pharmaceutical and tobacco companies. JAMA. 2002 Aug 14; 288(6):738-44.
    View in: PubMed
    Score: 0.181
  28. Pokorny AMJ, Fabbri A, Bero LA, Moynihan R, Mintzes BJ. Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review. Br J Cancer. 2022 01; 126(1):144-161.
    View in: PubMed
    Score: 0.170
  29. Fabbri A, Nejstgaard CH, Grundy Q, Bero L, Dunn AG, Mohammad A, Mintzes B. Association Between Conflicts of Interest and Authors' Positions on Harms of Varenicline: a Cross-Sectional Analysis. J Gen Intern Med. 2022 02; 37(2):290-297.
    View in: PubMed
    Score: 0.166
  30. Parker L, Grundy Q, Fabbri A, Mintzes B, Bero L. 'Lines in the sand': an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders. BMJ Open. 2021 02 09; 11(2):e045140.
    View in: PubMed
    Score: 0.163
  31. Parker L, Bennett A, Mintzes B, Grundy Q, Fabbri A, Karanges EA, Bero L. "There are ways ? drug companies will get into DTC decisions": How Australian drug and therapeutics committees address pharmaceutical industry influence. Br J Clin Pharmacol. 2021 05; 87(5):2341-2353.
    View in: PubMed
    Score: 0.161
  32. Moynihan R, Macdonald H, Bero L, Godlee F. Commercial influence and covid-19. BMJ. 2020 06 24; 369:m2456.
    View in: PubMed
    Score: 0.156
  33. Moynihan R, Albarqouni L, Nangla C, Dunn AG, Lexchin J, Bero L. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. BMJ. 2020 05 27; 369:m1505.
    View in: PubMed
    Score: 0.155
  34. Turner K, Carboni-Jim?nez A, Benea C, Elder K, Levis B, Boruff J, Roseman M, Bero L, Lexchin J, Turner EH, Benedetti A, Thombs BD. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. BMJ Open. 2020 05 11; 10(5):e035633.
    View in: PubMed
    Score: 0.155
  35. Rasmussen K, Bero L, Redberg R, G?tzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ. 2018 Oct 03; 363:k3654.
    View in: PubMed
    Score: 0.138
  36. Grundy Q, Held F, Bero L. A Social Network Analysis of the Financial Links Backing Health and Fitness Apps. Am J Public Health. 2017 11; 107(11):1783-1788.
    View in: PubMed
    Score: 0.129
  37. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017 02 16; 2:MR000033.
    View in: PubMed
    Score: 0.124
  38. Stryer D, Bero LA. Characteristics of materials distributed by drug companies. An evaluation of appropriateness. J Gen Intern Med. 1996 Oct; 11(10):575-83.
    View in: PubMed
    Score: 0.121
  39. Grundy Q, Bero LA, Malone RE. Marketing and the Most Trusted Profession: The Invisible Interactions Between Registered Nurses and Industry. Ann Intern Med. 2016 06 07; 164(11):733-9.
    View in: PubMed
    Score: 0.117
  40. Stryer DB, Lurie P, Bero LA. Dear doctor ... regarding calcium channel blockers. JAMA. 1996 Feb 21; 275(7):517-9.
    View in: PubMed
    Score: 0.116
  41. Stryer DB, Bero LA. Drug promotion. N Engl J Med. 1995 Apr 13; 332(15):1032; author reply 1033.
    View in: PubMed
    Score: 0.109
  42. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. Cochrane Database Syst Rev. 2013 Dec 20; (12):ED000075.
    View in: PubMed
    Score: 0.099
  43. Grundy Q, Bero L, Malone R. Interactions between non-physician clinicians and industry: a systematic review. PLoS Med. 2013 Nov; 10(11):e1001561.
    View in: PubMed
    Score: 0.099
  44. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012 Dec 12; 12:MR000033.
    View in: PubMed
    Score: 0.093
  45. Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med. 1992 Oct 15; 327(16):1135-40.
    View in: PubMed
    Score: 0.092
  46. Bero L, Carson B, Moller H, Hill S. To give is better than to receive: compliance with WHO guidelines for drug donations during 2000-2008. Bull World Health Organ. 2010 Dec 01; 88(12):922-9.
    View in: PubMed
    Score: 0.079
  47. Robertson J, Walkom E, Moynihan R, Bero L, Henry D. Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharm Pract. 2010 Apr; 18(2):88-92.
    View in: PubMed
    Score: 0.077
  48. Robertson J, Moynihan R, Walkom E, Bero L, Henry D. Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med. 2009 Nov; 6(11):e1000128.
    View in: PubMed
    Score: 0.075
  49. Bero L. "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise. J Clin Epidemiol. 2008 Jul; 61(7):629-33.
    View in: PubMed
    Score: 0.068
  50. Bero L. [Shall we ban industrial funds for research?]. Epidemiol Prev. 2007 Jul-Aug; 31(4):171-4.
    View in: PubMed
    Score: 0.063
  51. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007 Jun; 4(6):e184.
    View in: PubMed
    Score: 0.063
  52. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006 Aug 15; 145(4):284-93.
    View in: PubMed
    Score: 0.060
  53. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31; 326(7400):1167-70.
    View in: PubMed
    Score: 0.048
  54. Pokorny AMJ, Moynihan R, Fox P, Karikios DJ, Bero LA, Mintzes BJ. Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions. JCO Oncol Pract. 2022 07; 18(7):e1154-e1163.
    View in: PubMed
    Score: 0.044
  55. Pokorny AMJ, Bero LA, Moynihan R, Mintzes BJ. Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly available disclosures. Intern Med J. 2021 Nov; 51(11):1816-1824.
    View in: PubMed
    Score: 0.043
  56. Nejstgaard CH, Bero L, Hr?bjartsson A, J?rgensen AW, J?rgensen KJ, Le M, Lundh A. Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations. Cochrane Database Syst Rev. 2020 12 08; 12:MR000040.
    View in: PubMed
    Score: 0.040
  57. Benea C, Turner KA, Roseman M, Bero LA, Lexchin J, Turner EH, Thombs BD. Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. Syst Rev. 2020 04 08; 9(1):77.
    View in: PubMed
    Score: 0.038
  58. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996 Mar 01; 124(5):485-9.
    View in: PubMed
    Score: 0.029
  59. Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996; 12(2):209-37.
    View in: PubMed
    Score: 0.029
  60. Hornbein T, Bero L, Rennie D. The publication of commercially supported supplements statement. Anesth Analg. 1995 Oct; 81(4):887-8; author reply 888-9.
    View in: PubMed
    Score: 0.028
  61. Moynihan R, Nickel B, Hersch J, Beller E, Doust J, Compton S, Barratt A, Bero L, McCaffery K. Public Opinions about Overdiagnosis: A National Community Survey. PLoS One. 2015; 10(5):e0125165.
    View in: PubMed
    Score: 0.027
  62. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011 Mar 09; 305(10):1008-17.
    View in: PubMed
    Score: 0.020
  63. Ridge AL, Bero LA, Hill SR. Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia. BMC Health Serv Res. 2010 Dec 16; 10:340.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)